Beta-Hydroxybutyrate Protects Liver from Sepsis Through Novel Protein Modification
Ketone body β-OHB prevents sepsis-induced liver damage by modifying antioxidant enzyme SOD2, offering new therapeutic approach.
Summary
Researchers discovered that β-hydroxybutyrate (β-OHB), a ketone body produced during fasting or ketogenic diets, protects the liver from sepsis-induced damage through a previously unknown mechanism. The study found that β-OHB chemically modifies a key antioxidant enzyme called SOD2, preventing its breakdown and enhancing its protective effects against harmful reactive oxygen species. This modification reduces inflammation and cell death in liver tissue during sepsis, suggesting ketone supplementation could be a therapeutic strategy for severe infections.
Detailed Summary
This groundbreaking study reveals how β-hydroxybutyrate (β-OHB), the primary ketone body produced during fasting or ketogenic diets, protects liver tissue from sepsis-induced damage through a novel protein modification mechanism. The research addresses a critical clinical need, as liver dysfunction occurs early in sepsis and significantly increases mortality risk.
Using mouse models and cell culture experiments, researchers demonstrated that β-OHB induces a chemical modification called β-hydroxybutyrylation (Kbhb) on superoxide dismutase 2 (SOD2), a crucial mitochondrial antioxidant enzyme. Specifically, β-OHB modified lysine 68 on the SOD2 protein, preventing its degradation by cellular machinery and stabilizing the enzyme. This modification increased SOD2 enzymatic activity and reduced harmful reactive oxygen species accumulation in both liver cells and immune cells.
In sepsis experiments using lipopolysaccharide (LPS) to induce liver injury, mice pretreated with ketone ester (which elevates β-OHB levels) showed significantly reduced liver damage markers including ALT and AST enzymes. The protective effect was lost when researchers used a mutant version of SOD2 that couldn't be modified by β-OHB, proving this specific modification was essential for protection.
The mechanism works by suppressing NLRP3 inflammasome activation in immune cells and preventing programmed cell death in liver cells. When SOD2 was properly modified by β-OHB, it maintained cellular antioxidant defenses, reducing the inflammatory cascade that drives sepsis-related organ damage.
These findings identify a previously unrecognized antioxidant pathway and suggest therapeutic potential for ketone supplementation in sepsis treatment. However, the study was conducted in mice, and human trials would be needed to confirm clinical applicability.
Key Findings
- β-OHB treatment increased SOD2 protein stability and enzymatic activity through lysine 68 modification
- Ketone ester pretreatment significantly reduced liver injury markers ALT and AST in LPS-induced sepsis
- SOD2 modification by β-OHB reduced mitochondrial ROS accumulation in both macrophages and hepatocytes
- Protective effects were completely abolished when SOD2 lysine 68 was mutated to prevent modification
- β-OHB treatment suppressed NLRP3 inflammasome activation and reduced IL-1β production
- Modified SOD2 prevented hepatocyte apoptosis by reducing caspase-3 activation
- Global proteomic analysis identified 3,469 upregulated Kbhb sites across 1,549 proteins in β-OHB-treated cells
Methodology
Researchers used C57BL/6 mice (n=6 per group) treated with ketone ester (3 mg/g/d for 3 days) before LPS-induced sepsis. Cell culture studies employed J774A.1 macrophages and AML12 hepatocytes treated with 2.5-5 mM β-OHB. Site-directed mutagenesis created SOD2 variants, and AAV8 vectors delivered wild-type or mutant SOD2 to mice. Statistical analysis used one-way ANOVA with Tukey's post-hoc testing.
Study Limitations
The study was conducted entirely in mouse models and cell cultures, requiring human clinical trials to confirm therapeutic potential. The researchers did not report conflicts of interest, but the specific ketone ester dosing and timing protocols would need optimization for clinical use. Long-term safety of sustained ketone elevation in critically ill patients remains unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.